IGJ Suspends Amsterdam Crack Trial Over Manufacturing Issues

Regulatory Halt Triggers Manufacturing Scrutiny

The regulatory body ordered the stoppage without publicly disclosing concrete details behind its decision. According to an IGJ spokesperson, the suspension directly relates to manufacturing issues surrounding the pharmaceutical compound utilized in the trial. “We are concerned about that,” the spokesperson stated, declining to elaborate further on the exact nature of the regulatory worries.

Amsterdam municipal officials learned of the shutdown two weeks prior to public disclosure, expressing frustration that a treatment protocol reaching clinical practice faces sudden disruption. The municipality, alongside the Ministry of Health and the IGJ, faces urgent calls to clarify the production questions and determine whether the research can resume following procedural adjustments.

Setbacks for Clinical Trials and Participants

Emeritus Professor of Addiction Care Wim van den Brink, who is closely connected to the municipal initiative, expressed surprise at the sudden halt. “We have cautiously informed the clients testing the substance and their treating physicians,” van den Brink noted.

Researchers view the intervention as a significant setback because the medication effectively eliminates the physiological drive to consume crack cocaine. Clinical observations indicate that trial participants under the dexamfetamine protocol experience reduced confusion and decreased financial pressure to fund their drug habits through theft. With the inspection procedure still active, the IGJ maintains that further public comment remains restricted while legal and regulatory reviews continue.

Urban Addiction Crisis and Rising Consumption

The suspension arrives amid an escalating public health challenge concerning crack cocaine availability in urban centers across the Netherlands. Data published by the Trimbos-Institute highlights a sharp rise in overall crack consumption in recent years, making visible drug use increasingly common in public spaces such as city parks and transit stations.

Amsterdam has spent twelve years investigating substitution therapies for crack dependence, eventually bringing the ADHD medication directly into local treatment rooms. Researchers observe that roughly one-third of individuals struggling with crack addiction also present with ADHD symptoms, providing a clinical rationale for testing targeted stimulant substitution therapies.

Exploring Alternative Treatments by 2027

To address the treatment gap, researchers continue exploring parallel methodologies to manage dependence. One alternative avenue involves investigating whether medical-grade crack cocaine can be prescribed in controlled clinical settings, similar to established heroin-assisted treatment programs.

That alternative remains in early exploratory phases, with researchers actively polling users and examining production pathways for a smokable pharmaceutical alternative that could potentially materialize by 2027. Scientists are also evaluating lisdexamfetamine—a prodrug activated within the bloodstream—as a secondary substitution candidate for patients suffering from persistent crack addiction.